Products with Anti-inflammatory bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN4997 | Angoroside C |
| Angoroside C has anti-inflammatory effect , it can significantly inhibit LPS-induced PGE(2), NO and TNF-alpha in a concentration-dependent manner; it also exhibits cytotoxic and cytostatic activities against several kinds of cancer cells. Angoroside C has beneficial effects against ventricular remodeling, the mechanism is likely to be related to decreasing the level of Ang Ⅱ, attenuating the mRNA expressions of ET-1 and TGF-β1. | |
| BCN5003 | Isocorynoxeine |
| Isocorynoxeine, an isorhynchophylline-related alkaloid, exhibits a dose-dependent inhibition of 5-HT2A receptor-mediated current response with an IC50 of 72.4 μM. Isocorynoxeine shows the effects of lowering blood pressure, vasodilatation, and protection against ischemia-induced neuronal damage, it exhibits a significant neuroprotective effect against glutamate-induced HT22 cell death at the maximum concentration. | |
| BCN5007 | Cornuside |
| Cornuside has immunomodulatory, and anti-inflammatory activities, it has protective potential against cerebral ischemic injury, may be due to the suppression of intracellular Ca(2+) elevation and caspase-3 activity, and improvements in mitochondrial energy metabolism and antioxidant properties. Cornuside can treat myocardial I/R and protect the liver from CCl₄-induced acute hepatotoxicity, by reducing oxidative stress and suppressing inflammatory responses. | |
| BCN5010 | Esculentoside A |
| Esculentoside A has anti-inflammatory activity , can suppress inflammatory responses in LPS-induced ALI through inhibition of the nuclear factor kappa B and mitogen activated protein kinase signaling pathways. Esculentoside A may be useful for the treatment of autoimmune disease through modulation on T cell-mediated adaptive immunity. Esculentoside A treatment can attenuate CCl4 and GalN/LPS-induced acute liver injury in mice. | |
| BCN5015 | Byakangelicol |
| Byakangelicol exhibits hepatoprotective activities on tacrine-induced cytotoxicity in Hep G2 cells, with EC(50) values of 112.7 +/- 5.35 microM. Byakangelicol may have therapeutic potential as an anti-inflammatory drug on airway inflammation, it can inhibit IL-1beta-induced PGE2 release in A549 cells; this inhibition may be mediated by suppression of COX-2 expression and the activity of COX-2 enzyme, it also can inhibit P-gp expressed. Byakangelicol shows a significant inhibition on the proliferation of cultured human tumor cells. | |
